Advanced search
Publication Cover
Epigenomics Volume 4, 2012 - Issue 5
Submit an article Journal homepage
313
Views
0
CrossRef citations to date
0
Altmetric
Review

Chromatin Regulators with Tumor Suppressor Properties and their Alterations in Human Cancers

Xing-Sheng Shu1 Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer & Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong KongView further author information
,
Lili Li1 Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer & Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong KongView further author information
&
Qian Tao1 Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer & Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong KongCorrespondence[email protected]
View further author information
Pages 537-549 | Published online: 06 Nov 2012

References

  • Li B , CareyM, WorkmanJL. The role of chromatin during transcription. Cell128(4) , 707–719 (2007).
  • Ram O , GorenA, AmitIet al. Combinatorial patterning of chromatin regulators uncovered by genome-wide location analysis in human cells. Cell 147(7) , 1628–1639 (2011).
  • Baylin SB , OhmJE. Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer6(2) , 107–116 (2006).
  • Rodriguez-Paredes M , EstellerM. Cancer epigenetics reaches mainstream oncology. Nat. Med.17(3) , 330–339 (2011).
  • Chi P , AllisCD, WangGG. Covalent histone modifications – miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer10(7) , 457–469 (2010).
  • Tsai MC , SpitaleRC, ChangHY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res.71(1) , 3–7 (2011).
  • Kouzarides T . Chromatin modifications and their function. Cell128(4) , 693–705 (2007).
  • Strahl BD , AllisCD. The language of covalent histone modifications. Nature403(6765) , 41–45 (2000).
  • Smith E , ShilatifardA. The chromatin signaling pathway: diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes. Mol. Cell40(5) , 689–701 (2010).
  • Shahbazian MD , GrunsteinM. Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem.76 , 75–100 (2007).
  • Minucci S , PelicciPG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer6(1) , 38–51 (2006).
  • Gu W , RoederRG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell90(4) , 595–606 (1997).
  • Ito A , LaiCH, ZhaoXet al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20(6) , 1331–1340 (2001).
  • Ferrari R , PellegriniM, HorwitzGA, XieW, BerkAJ, KurdistaniSK. Epigenetic reprogramming by adenovirus e1a. Science321(5892) , 1086–1088 (2008).
  • Gayther SA , BatleySJ, LingerLet al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24(3) , 300–303 (2000).
  • Muraoka M , KonishiM, Kikuchi-YanoshitaRet al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene12(7) , 1565–1569 (1996).
  • Petrij F , GilesRH, DauwerseHGet al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376(6538) , 348–351 (1995).
  • Borrow J , StantonVP Jr, Andresen JM et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet.14(1) , 33–41 (1996).
  • Zhao LY , LiuY, BertosNR, YangXJ, LiaoD. PCAF is a coactivator for p73-mediated transactivation. Oncogene22(51) , 8316–8329 (2003).
  • Zhu C , QinYR, XieDet al. Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma. Oncogene 28(31) , 2821–2828 (2009).
  • Ozdag H , BatleySJ, ForstiAet al. Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours. Br. J. Cancer 87(10) , 1162–1165 (2002).
  • Halkidou K , GaughanL, CookS, LeungHY, NealDE, RobsonCN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate59(2) , 177–189 (2004).
  • Wilson AJ , ByunDS, PopovaNet al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 281(19) , 13548–13558 (2006).
  • Bolden JE , PeartMJ, JohnstoneRW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov.5(9) , 769–784 (2006).
  • Ropero S , FragaMF, BallestarEet al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 38(5) , 566–569 (2006).
  • Frolov MV , DysonNJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J. Cell. Sci.117(Pt 11) , 2173–2181 (2004).
  • Rodriguez RM , FragaMF. Aging and cancer: are sirtuins the link? Future Oncol.6(6) , 905–915 (2010).
  • Saunders LR , VerdinE. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene26(37) , 5489–5504 (2007).
  • Wang RH , SenguptaK, LiCet al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14(4) , 312–323 (2008).
  • Powell MJ , CasimiroMC, Cordon-CardoCet al. Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation. Cancer Res. 71(3) , 964–975 (2010).
  • Kim HS , VassilopoulosA, WangRHet al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20(4) , 487–499 (2011).
  • Finley LW , CarracedoA, LeeJet al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell 19(3) , 416–428 (2011).
  • Semenza GL . HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev.20(1) , 51–56 (2010).
  • Kim HS , PatelK, Muldoon-JacobsKet al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17(1) , 41–52 (2010).
  • Mosammaparast N , ShiY. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu. Rev. Biochem.79 , 155–179 (2010).
  • Beisel C , ParoR. Silencing chromatin: comparing modes and mechanisms. Nat. Rev. Genet.12(2) , 123–135 (2011).
  • He L , YuJX, LiuLet al. RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2–M cell cycle arrest and/or apoptosis. Cancer Res. 58(19) , 4238–4244 (1998).
  • Kim KC , GengL, HuangS. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res.63(22) , 7619–7623 (2003).
  • Du Y , CarlingT, FangW, PiaoZ, SheuJC, HuangS. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res.61(22) , 8094–8099 (2001).
  • Oshimo Y , OueN, MitaniYet al. Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int. J. Cancer 110(2) , 212–218 (2004).
  • Xie P , TianC, AnLet al. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. Cell Signal 20(9) , 1671–1678 (2008).
  • Chuikov S , KurashJK, WilsonJRet al. Regulation of p53 activity through lysine methylation. Nature 432(7015) , 353–360 (2004).
  • Lehnertz B , RogalskiJC, SchulzeFMet al. p53-dependent transcription and tumor suppression are not affected in Set7/9-deficient mice. Mol. Cell 43(4) , 673–680 (2011).
  • Al Sarakbi W , SasiW, JiangWG, RobertsT, NewboldRF, MokbelK. The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters. BMC Cancer9 , 290 (2009).
  • Dalgliesh GL , FurgeK, GreenmanCet al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279) , 360–363 (2010).
  • Duns G , van den Berg E, van Duivenbode I et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res.70(11) , 4287–4291 (2010).
  • Zhang J , DingL, HolmfeldtLet al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481(7380) , 157–163 (2012).
  • Morishita M , di Luccio E. Cancers and the NSD family of histone lysine methyltransferases. Biochim. Biophys. Acta1816(2) , 158–163 (2011).
  • Marango J , ShimoyamaM, NishioHet al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 111(6) , 3145–3154 (2008).
  • Berdasco M , RoperoS, SetienFet al. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc. Natl Acad. Sci. USA 106(51) , 21830–21835 (2009).
  • Kim SM , KeeHJ, ChoeN, KimJY, KookH, SeoSB. The histone methyltransferase activity of WHISTLE is important for the induction of apoptosis and HDAC1-mediated transcriptional repression. Exp. Cell Res.313(5) , 975–983 (2007).
  • Zhou Z , ThomsenR, KahnsS, NielsenAL. The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells. Biochem. Biophys. Res. Commun.398(3) , 565–570 (2010).
  • Shi Y . Histone lysine demethylases: emerging roles in development, physiology and disease. Nat. Rev. Genet.8(11) , 829–833 (2007).
  • Shi Y , LanF, MatsonCet al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119(7) , 941–953 (2004).
  • Wang Y , ZhangH, ChenYet al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138(4) , 660–672 (2009).
  • Hayami S , KellyJD, ChoHSet al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128(3) , 574–586 (2010).
  • Huang J , SenguptaR, EspejoABet al. p53 is regulated by the lysine demethylase LSD1. Nature 449(7158) , 105–108 (2007).
  • Harris WJ , HuangX, LynchJTet al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21(4) , 473–487 (2012).
  • Hong S , ChoYW, YuLR, YuH, VeenstraTD, GeK. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc. Natl Acad. Sci. USA104(47) , 18439–18444 (2007).
  • van Haaften G , DalglieshGL, DaviesHet al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41(5) , 521–523 (2009).
  • Herz HM , MaddenLD, ChenZet al. The H3K27me3 demethylase dUTX is a suppressor of Notch- and Rb-dependent tumors in Drosophila. Mol. Cell. Biol.30(10) , 2485–2497 (2010).
  • Wang JK , TsaiMC, PoulinGet al. The histone demethylase UTX enables RB-dependent cell fate control. Genes Dev. 24(4) , 327–332 (2010).
  • Agger K , CloosPA, RudkjaerLet al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A–ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 23(10) , 1171–1176 (2009).
  • Niu X , ZhangT, LiaoLet al. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 31(6) , 776–786 (2011).
  • Osawa T , MuramatsuM, WangFet al. Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis. Proc. Natl Acad. Sci. USA 108(51) , 20725–20729 (2011).
  • Li Q , ShiL, GuiBet al. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res. 71(21) , 6899–6908 (2011).
  • Nijwening JH , GeutjesEJ, BernardsR, BeijersbergenRL. The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescence. PLoS ONE6(9) , e25235 (2011).
  • Ho L , CrabtreeGR. Chromatin remodelling during development. Nature463(7280) , 474–484 (2010).
  • Roberts CW , OrkinSH. The SWI/SNF complex – chromatin and cancer. Nat. Rev. Cancer4(2) , 133–142 (2004).
  • Wilson BG , RobertsCW. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer11(7) , 481–492 (2011).
  • Versteege I , SevenetN, LangeJet al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394(6689) , 203–206 (1998).
  • Sevenet N , SheridanE, AmramD, SchneiderP, HandgretingerR, DelattreO. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am. J. Hum. Genet.65(5) , 1342–1348 (1999).
  • Roberts CW , GalushaSA, McMenaminME, FletcherCD, OrkinSH. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc. Natl Acad. Sci. USA97(25) , 13796–13800 (2000).
  • Roberts CW , LerouxMM, FlemingMD, OrkinSH. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell2(5) , 415–425 (2002).
  • Zhang ZK , DaviesKP, AllenJet al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol. Cell. Biol. 22(16) , 5975–5988 (2002).
  • Isakoff MS , SansamCG, TamayoPet al. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc. Natl Acad. Sci. USA 102(49) , 17745–17750 (2005).
  • Wilson BG , WangX, ShenXet al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18(4) , 316–328 (2010).
  • McKenna ES , SansamCG, ChoYJet al. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol. Cell. Biol. 28(20) , 6223–6233 (2008).
  • Yamamichi N , Yamamichi-NishinaM, MizutaniTet al. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene 24(35) , 5471–5481 (2005).
  • Wong AK , ShanahanF, ChenYet al. BRG1, a component of the SWI–SNF complex, is mutated in multiple human tumor cell lines. Cancer Res. 60(21) , 6171–6177 (2000).
  • Rodriguez-Nieto S , CanadaA, ProsEet al. Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors. Hum. Mutat. 32(2) , e1999–e2017 (2011).
  • Bock VL , LyonsJG, HuangXXet al. BRM and BRG1 subunits of the SWI/SNF chromatin remodelling complex are downregulated upon progression of benign skin lesions into invasive tumours. Br. J. Dermatol. 164(6) , 1221–1227 (2011).
  • Shen H , PowersN, SainiNet al. The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res. 68(24) , 10154–10162 (2008).
  • Alessio N , SquillaroT, CipollaroM, BagellaL, GiordanoA, GalderisiU. The BRG1 ATPase of chromatin remodeling complexes is involved in modulation of mesenchymal stem cell senescence through RB-P53 pathways. Oncogene29(40) , 5452–5463 (2010).
  • Dunaief JL , StroberBE, GuhaSet al. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 79(1) , 119–130 (1994).
  • Strobeck MW , ReismanDN, GunawardenaRWet al. Compensation of BRG-1 function by Brm: insight into the role of the core SWI–SNF subunits in retinoblastoma tumor suppressor signaling. J. Biol. Chem. 277(7) , 4782–4789 (2002).
  • Becker TM , HaferkampS, DijkstraMKet al. The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Mol. Cancer 8 , 4 (2009).
  • Strobeck MW , KnudsenKE, FribourgAFet al. BRG-1 is required for RB-mediated cell cycle arrest. Proc. Natl Acad. Sci. USA 97(14) , 7748–7753 (2000).
  • Bultman SJ , HerschkowitzJI, GodfreyVet al. Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene 27(4) , 460–468 (2008).
  • Huang J , ZhaoYL, LiY, FletcherJA, XiaoS. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer46(8) , 745–750 (2007).
  • Mamo A , CavalloneL, TuzmenSet al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 31(16) , 2090–2100 (2012).
  • Jones S , WangTL, Shih IeM et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science330(6001) , 228–231 (2010).
  • Wiegand KC , ShahSP, Al-AghaOMet al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med.363(16) , 1532–1543 (2010).
  • Wang K , KanJ, YuenSTet al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 43(12) , 1219–1223 (2011).
  • Jones S , LiM, ParsonsDWet al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum. Mutat. 33(1) , 100–103 (2012).
  • Fujimoto A , TotokiY, AbeTet al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44(7) , 760–764 (2012).
  • Nagl NG Jr, Zweitzig DR, Thimmapaya B, Beck GR Jr, Moran E. The c-myc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest. Cancer Res.66(3) , 1289–1293 (2006).
  • Guan B , WangTL, Shih IeM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res.71(21) , 6718–6727 (2011).
  • Li M , ZhaoH, ZhangXet al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43(9) , 828–829 (2011).
  • Yan Z , CuiK, MurrayDMet al. PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. Genes Dev. 19(14) , 1662–1667 (2005).
  • Xia W , NagaseS, MontiaAGet al. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res. 68(6) , 1667–1674 (2008).
  • Varela I , TarpeyP, RaineKet al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331) , 539–542 (2011).
  • Drost J , MantovaniF, ToccoFet al. BRD7 is a candidate tumour suppressor gene required for p53 function. Nat. Cell. Biol.12(4) , 380–389 (2010).
  • Liu H , ZhangL, NiuZet al. Promoter methylation inhibits BRD7 expression in human nasopharyngeal carcinoma cells. BMC Cancer 8 , 253 (2008).
  • Lin JR , ZemanMK, ChenJY, YeeMC, CimprichKA. SHPRH and HLTF act in a damage-specific manner to coordinate different forms of postreplication repair and prevent mutagenesis. Mol. Cell42(2) , 237–249 (2011).
  • Moinova HR , ChenWD, ShenLet al. HLTF gene silencing in human colon cancer. Proc. Natl Acad. Sci. USA99(7) , 4562–4567 (2002).
  • Hamai Y , OueN, MitaniYet al. DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma. Cancer Sci. 94(8) , 692–698 (2003).
  • Herbst A , WallnerM, RahmigKet al. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur. J. Gastroenterol. Hepatol. 21(5) , 565–569 (2009).
  • Kim JJ , ChungSW, KimJHet al. Promoter methylation of helicase-like transcription factor is associated with the early stages of gastric cancer with family history. Ann. Oncol. 17(4) , 657–662 (2006).
  • Nagarajan P , OnamiTM, RajagopalanS, KaniaS, DonnellR, VenkatachalamS. Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis. Oncogene28(8) , 1053–1062 (2009).
  • Bagchi A , PapazogluC, WuYet al. CHD5 is a tumor suppressor at human 1p36. Cell 128(3) , 459–475 (2007).
  • Kim MS , ChungNG, KangMR, YooNJ, LeeSH. Genetic and expressional alterations of CHD genes in gastric and colorectal cancers. Histopathology58(5) , 660–668 (2011).
  • Gorringe KL , ChoongDY, WilliamsLHet al. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 10(11) , 1253–1258 (2008).
  • Fujita T , IgarashiJ, OkawaERet al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J. Natl Cancer Inst.100(13) , 940–949 (2008).
  • Mulero-Navarro S , EstellerM. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics3(4) , 210–215 (2008).
  • Garcia I , MayolG, RodriguezEet al. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol. Cancer 9 , 277 (2010).
  • Wong RR , ChanLK, TsangTPet al. CHD5 downregulation associated with poor prognosis in epithelial ovarian cancer. Gynecol. Obstet. Invest.72(3) , 203–207 (2011).
  • Zang ZJ , CutcutacheI, PoonSLet al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44(5) , 570–574 (2012).
  • Schwartzentruber J , KorshunovA, LiuXYet al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384) , 226–231 (2012).
  • Wu G , BroniscerA, McEachronTAet al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44(3) , 251–253 (2012).
  • Seligson DB , HorvathS, ShiTet al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435(7046) , 1262–1266 (2005).
  • Barlesi F , GiacconeG, Gallegos-RuizMIet al. Global histone modifications predict prognosis of resected non-small-cell lung cancer. J. Clin. Oncol. 25(28) , 4358–4364 (2007).
  • Chadwick RB , JiangGL, BenningtonGAet al. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc. Natl Acad. Sci. USA 97(6) , 2662–2667 (2000).
  • Zhang C , LiH, WangYet al. Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications. J. Hepatol. 53(5) , 889–895 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.